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CholestasisNuclear receptor signalling is essential for physiological processes such as metabolism, development, and
reproduction. Alterations in the endocrine state that naturally occur during pregnancy result in maternal
adaptations to support the feto-placental unit. A series of studies have shown that nuclear receptor signalling
is involved in maternal adaptations of bile acid, cholesterol, and lipid homeostasis pathways to ensure
maintenance of the nutritional demands of the fetus. We discuss regulation of hepatic nuclear receptors and
their target genes in pregnancy and their impact on the development of disorders such as intrahepatic
cholestasis of pregnancy and oestrogen-induced hepatotoxicity. This article is part of a Special Issue entitled:
Translating nuclear receptors from health to disease.slating nuclear receptors from
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There are profound alterations in the maternal hormonal milieu to
support the feto-placental unit during pregnancy. Increased demand
on the maternal hepatic functional activity is one of the major
adaptations required tomeet the nutritional development of the fetus.
Any deﬁciencies in this process may have adverse outcomes for both
the mother and the fetus, especially in the context of genetic
predisposition to hepatic impairment. Recent studies have shown
that hepatic nuclear receptor signalling is an important component of
the mechanisms that coordinate metabolic processes during pregnan-
cy. The scope of this review is to give an overview of what is known
about the regulation and role of hepatic nuclear receptor function in
bile acid, cholesterol, and lipid homeostasis during pregnancy.
2. Metabolic pathways are altered during pregnancy to support
the developing feto-placental unit
Pregnancy is characterised by marked physiological adaptations of
the mother that are essential for maintenance and growth of the feto-
placental unit. Profound hormonal changes occur; the placenta
synthesises large amounts of steroid hormones that are secreted tothe maternal and fetal units. The mother, and to a lesser extent the
fetus, is exposed to high levels of progestogens, oestrogens, miner-
alocorticoids, and glucocorticoids. Moreover, large quantities of
prostaglandins, prolactin, and placental lactogen are released into
the maternal compartment in the third trimester of pregnancy.
Whereas most attention has been given to the effects of pregnancy
and steroid reproductive hormones on reproductive endocrine
tissues, gestational effects on metabolic tissues such as the liver
have not been studied extensively. It is well established that changes
in gestational hormones coincide with dramatic maternal hepatic
metabolic adaptations that serve to increase the liver's functional
capacity to produce the nutritional and metabolic molecules needed
for the developing placenta and fetus. Thus, there are alterations in
uptake, storage, and distribution of nutrients and vitamins, homeo-
static mechanisms formaintenance of blood sugar levels, regulation of
circulating plasma lipids, the synthesis of circulating plasma proteins,
and metabolism of nutrients, toxic compounds, and drugs [1–3]. This
requires systemic alterations in hepatic cholesterol, lipid, glucose, and
bile acid homeostasis [4–10] (Table 1). In a subgroup of pregnant
women, pregnancy increases susceptibility to metabolic disorders of
the liver, such as intrahepatic cholestasis of pregnancy (ICP),
especially when they are genetically predisposed.
Hepatic nuclear receptors may be key signalling components that
transduce the necessary changes in hepatic lipid metabolism during
pregnancy. There are very limited studies of hepatic regulation of
gestational metabolic proﬁles, and most of them are restricted to
animal models as it is not ethically acceptable to take liver biopsies
from healthy pregnant women.
Table 1
Biochemical metabolic features of human pregnancy.
Biochemical change Direction Reference
Free fatty acids ↑ [9,14]
Triglycerides ↑ [4]
Total cholesterol ↑ [13]
Apo-B ↑ [4]
LDL-C ↑ [4]
HDL-C ↓ [4]
Apo-A1 ↓ [4]
Bile acids ↑ [10,95]
Insulin ↑ [9,14]
Glucose ↑ [5]
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Thenuclear receptor family comprises ligand-activated transcription
factors that regulate genes with central roles in physiological processes
such as metabolism, reproduction and development. In the human
genome, at least 48 nuclear receptors have been identiﬁed with
functional and structural similarities to nuclear receptors in Caenorhab-
ditis elegans, indicating an ancient metazoan origin for this family [11].
To date, nuclear receptors have been divided in two groups; both share
similar structural and functional characteristics. The ﬁrst group
comprises the classic endocrine nuclear receptors, i.e. thyroid, proges-
terone, oestrogen, androgen, mineralocorticoid, and glucocorticoid
receptors (TR, PR, ER, AR, MR, and GR) that are activated by hormonal
lipids that are bound with high-afﬁnity to form homodimers in their
active state and are regulated by negative feedback control of the
hypothalamus–pituitary axis [12]. The second group includes the
orphan nuclear receptors that encompass the so-called lipid sensors,
activation of which is subject to binding of dietary lipids (typically with
low afﬁnity). Ligands include fatty acids, oxysterols, bile acids, and
xenobiotics that activate the peroxisome proliferator-activated recep-
tors (PPAR-α, β/δ, γ), liver x receptors (LXR-α, β), farnesoid x receptor
(FXR), and the pregnane x receptor (PXR) and constitutive androstane
receptor (CAR), respectively (hence the name adopted orphan nuclear
receptors). The adopted orphan nuclear receptors form heterodimers
with the retinoid x receptors (RXR-α, β, γ) when activated [13–15].
Upon activation, these receptors induce a feedforward metabolic
cascade to maintain homeostasis by coordinating a network of genes
withkey roles in lipidmetabolism, storage, transport, and clearance. TheTable 2
Nuclear receptor expression in rodent pregnancy.
Classic nuclear receptors Endogenous ligand Expression in li
Tr-α, Tr-β Tri-idothyronine Not known
Er-α, Εr-β 17β-Estradiol Yes
Ar 5α-Dihydro-testosterone No
Pr Progesterone No
Gr Corticosterone Yes
Mr Aldosterone Yes
Orphan nuclear receptors
Ppar-α, Ppar-γ, Ppar-β/δ Fatty acids Yes
Lxr-α, Lxr-β Oxysterols Yes
Fxr Hydrophobic bile acids;
CDCA, DCA, CA, LCA
Yes
Shp Not known;
transcriptionally activated by Fxr
Yes
Pxr Pregnenolone-16-carbonitrile,
LCA, DCA, CA
Yes
Car 5α-Androstan-3α-ol Yes
Hnf-4 Not known Yes
Lrh-1 Not known Yes
Rev-Erb-α Heme Yes
Rxr-α, Rxr-β, Rxr-γ 9-cis Retinoic acid Yes
CDCA: chenodeoxycholic acid, DCA: deoxycholic acid, CA: cholic acid, LCA: lithocholic acid.
a Our novel unpublished data.commonest gene families that are transcriptionally regulated by orphan
nuclear receptors are the P450 cytochrome metabolising enzymes
(CYPs), fatty acid binding proteins (FABPs), and ATP-binding cassette
(ABC) proteins [16,17]. Other orphan nuclear receptors include the
small heterodimer partner (SHP), an atypical nuclear receptor that acts
as a transcriptional repressor, the liver receptor homologue-1 (LRH-1),
and the hepatocyte nuclear factor-4 (HNF-4). Ligands of these receptors
are not known; however, they are induced by other nuclear receptors
[18,19]. REV-ERB-α is another orphan receptor that acts as a
transcriptional repressor and exists as a monomer or homodimer.
Heme has been identiﬁed as its physiological ligand [20–22]. All these
receptors have been shown to play an essential role in lipid and bile acid
homeostasis [23–27]. The main classic and orphan nuclear receptors
along with their endogenous ligands are summarised in Table 2.
4. Hepatic nuclear receptor gene expression levels are decreased
during pregnancy
Two independent studies in mouse and rat models have reported
decreased expression of hepatic orphan nuclear receptors in late
pregnancy [28,29]. Speciﬁcally, gene and protein expression studies in
pregnant mouse livers showed reduced expression of all the Rxr-α,
Rxr-β, and Rxr-γ that are essential partners for lipid sensor function as
well as reduced Ppar-α, Ppar-β/δ and Ppar-γ, Lxr-α and Lxr-β and Fxr,
Shp and Lrh-1 [28] (Table 2). Their target genes were also shown to
have reduced expression, indicating that late pregnancy is associated
with attenuated hepatic nuclear receptor signalling that in turn affects
fatty acid and triglyceride synthesis, cholesterol elimination and
storage, as well as bile acid homeostasis. Moreover, a microarray
analysis in the liver of pregnant rats revealed decreased expression
levels of xenobiotic receptors Pxr and Car [29] (Table 2). Intriguingly,
besides the abovementioned nuclear receptors, the gene expression
levels of the classic nuclear receptors, Gr and Mr, were reduced in late
pregnancy (Papacleovoulou et al., unpublished data; Table 2).
Detailed mechanisms of these processes have not yet been
identiﬁed. It is also not known whether reduced hepatic nuclear
receptor levels are the cause or a consequence of altered hepatic
metabolism in themother. However, this process appears to be part of
the maternal hepatic adaptations that secure energy storage and
mobilisation towards the feto-placental unit to maintain fetal growth
and development.ver Direction in rodent pregnancy Reference
Not known Not relevant
no change Papacleovoulou et al., unpublisheda
Not relevant Papacleovoulou et al., unpublisheda
Not relevant Papacleovoulou et al., unpublisheda
↓ Papacleovoulou et al., unpublisheda
↓ Papacleovoulou et al., unpublisheda
↓ [28]
↓ [28]
↓ [28,29]
↓ [28,29]
↓ [29]
↓ (Rat); no change (mice) [28,29]
No change [28]
↓ [28]
Not known Not relevant
↓ [28]
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As mentioned above, pregnancy is characterised by elevated serum
progesterone and oestrogen levels that are at their highest in the third
trimester when alterations in hepatic metabolism are also profound.
Several studies have suggested that rising levels of oestrogens
mediate metabolic adaptations in pregnancy. Early pregnancy is
associatedwith an increase in fat mass tomatch fetal and post-partum
nutrition. By 24 weeks of gestation, women gain an average of
approximately 4 kg of fat withoutmarked alterations in energy intake.
Moreover, fat oxidation is suppressed as pregnancy progresses,
whereas in post-menopausal women, fat oxidation is markedly
increased. This implies that oestrogens work in favour of fat
deposition required for reproduction and enables the shift from fat
storage to fat mobilisation towards the feto-placental unit without the
need for dietary changes [30].
Interestingly, of the two Er isoforms, Er-α and Er-β, Er-α is the
main isoform that is expressed in the liver and participates in hepatic
metabolism [31–33]. There is no evidence of nuclear progesterone
receptor (Pr) expression in the liver. Therefore, oestrogen-mediated
hepatic alterations in metabolism can be accomplished both directly
and indirectly, whereas progestogen effects on liver capacity are likely
to be exerted indirectly or through the membrane Pr, at least in
rodents [34]. In agreement with this concept, oestrogen-induced
hepatotoxicity in rodent models has been shown to be induced
through hepatic Er-α [35] and also through cross-talk with thyroid
tri-iodothyronine (T3) and pituitary growth hormone (Gh) [36,37].
Moreover, non-genomic effects of progesterone metabolites in
hepatic metabolism have been demonstrated [38,39].
5.1. Role of oestrogens in hepatic bile acid homeostatic pathways in mice
As referred to above, oestrogens affect hepatic function. A series of
studies have established that oestrogens impact the hepatic bile acid
signalling pathways (Fig. 1) and alter bile acid and lipid homeostatic
mechanisms, thereby causing hepatotoxicity and intrahepatic cholesta-
sis. Treatments with supraphysiological doses of 17α-ethynylestradiol
(EE2) in female mice altered the inﬂux and efﬂux of bile acids and
cholesterol [35,40–45]. Speciﬁcally, EE2 inhibited the expression of the
bile salt export pump (Bsep), a high-afﬁnity liver-speciﬁc transporter
that exports conjugated bile acids into the bile canaliculus [40–42] as
well as the Na+/taurocholate co-transporting polypeptide (Ntcp), the
most important determinant of bile acid uptake [43–45]. Additionally,
EE2 reduced the organic anion-transporting polypeptides (Oatp1/2) as
well as the expression of the biliary cholesterol transporters, Abcg5 andFig. 1. Hepatic bile acid homeostatic mechanisms. Hepatic bile acid detoxiﬁcation can be ach
are committed to be excreted through feces and urine. Accumulation of bile acids induces th
and bile acid import (↓ NTCP). FXR also activates bile acid export (↑ BSEP). 2. Alternative
excretion through feces and urine (↑ MRP4).Abcg8 [35], all very important for clearance of the intrinsic toxic bile
acids and maintenance of the enterohepatic circulation (Fig. 1). Altered
gene expression of bile acid and cholesterol transporters was accom-
panied by a disruption of the bile acid pool as shown by an increase in
the β-muricholic to cholic acid ratio. Mice lacking the Er-α were
resistant to these changes and did not develop liver damage and
intrahepatic cholestasis [35].
Both ethinylestradiol (EE2) and the glucuronidated oestrogen
metabolite oestradiol-17β-D-glucuronide (E2-17βG) have been
shown to cause cholestasis in rodent models [46–48]. EE2 adminis-
tration reduced murine Bsep, Ntcp, Oatp1, Oatp2, and Oatp4 mRNA
and protein expression [36,49,50], whereas E2-17βG has been shown
to alter the subcellular localisation of rat canalicular transporters,
speciﬁcally to induce internalisation of Bsep within submembrane
vesicles in rats [47] and microtubule-dependent internalisation of
Mrp2 [51]. Intriguingly, it was recently shown that phosphoinositide
3-kinase (PI3K) pathway is involved in E2-17βG-induced Bsep and
Mrp2 subcellular internalisation [46].
6. Er signalling is associatedwith pregnancy-inducedhepatotoxicity
and cholestasis in mice
Recent evidence suggests that attenuated orphan nuclear receptor
expression and function with accompanied alterations in hepatic
metabolism is a consequence of a crosstalk between the Er and the
orphan nuclear receptors, Fxr [52] and Ppar-α [53] at least in mice.
6.1. Attenuated Fxr function during mouse pregnancy
As discussed above, oestrogens affect a number of genes that are
involved in maintenance of bile acid homeostasis. Transcriptional
regulation of bile acid homeostasis-related genes is under the control
of the nuclear receptor, FXR. Activation of hepatic FXR leads to
detoxiﬁcation of bile acids through suppression of bile acid biosyn-
thesis and import. More precisely, FXR inhibits bile acid biosynthesis
and uptake through induction of SHP that directly or indirectly down-
regulates CYP7A1 (in human and rodents), CYP8B1 (in rodents only)
and NTCP (both human and rodents). Moreover, active FXR controls
export and excretion through up-regulation of BSEP, MRP3, andMDR1
[45,54–58]. An alternative route of hepatic bile acid detoxiﬁcation is
through sulphation and excretion through the feces [59] (Fig. 1).
A recent study in our laboratory demonstrated reduction of Fxr
function that may explain increased serum and hepatic bile acid levels
along with pro-cholestatic hepatic gene expression in mouse
pregnancy [52]. Speciﬁcally, it was established that late mouseieved through (1) FXR pathway activation and (2) sulphation of bile acids, so that they
e FXR pathway. As a result, SHP is activated to repress bile acid biosynthesis (↓ Cyp7a1)
excretion of bile acids is also achieved by sulphation (↑ Sult2a1) and commitment of
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transporter genes, Ntcp, Oatp2, Bsep, Mrp3, and Mdr1 mRNA along
with increased expression of bile acid synthesis genes, Cyp7a1 and
Cyp8b1. Moreover, pregnant mice had increased concentrations of
hepatic and serum bile acids. This transcriptional and biochemical
proﬁle was comparable to non-pregnant Fxr null mice, implying that
hepatic Fxr function is blunted at least in late pregnancy [52].
Consistent with this, hepatic Shp appeared to be down-regulated in
the livers of mice on day 18 of gestation. In the light of these ﬁndings,
in vivo studies in gonadectomised mice demonstrated that Shp mRNA
expression was abrogated in response to subcutaneous insertion of
slow-release silastic implants supplemented with 17β-oestradiol at
levels and for a duration that mimic pregnancy. Furthermore, in vitro
treatment of rat Fao liver cells with serum obtained from pregnant
women suppressed Shp mRNA expression and this effect was
reversed when the Er antagonist Fulvestrant was added. Failure to
inhibit Shp induction in response to co-treatment of bile acids with
pregnancy doses of 17β-oestradiol in vitro implied that oestrogen
metabolites and not oestradiol on its own are more likely to be
associated with loss of Fxr function [52]. Consistent with this,
oestradiol 17β-D-glucuronide has been shown to impair Bsep function
in Xenopus laevis oocytes expressing rat Bsep [38]. A schematic
summary of hepatic gene proﬁle in pregnant wild-type and non-
pregnant Fxr null mice is depicted in Fig. 2.
As referred to above, pharmacological treatment with EE2 in
female mice reduced mRNA expression of the bile acid biosynthetic
genes Cyp7a1 and Cyp8b1. However, Shp mRNA expression was
unaffected [35]. Moreover, in male rats [37] as well as in gonadecto-
mised female mice [19], EE2 treatment resulted in up-regulation of
Shp gene expression that in turn resulted in reduced Cyp7a1
transcript levels. In contrast, our studies showed that pregnant mice
and gonadectomised mice treated with a pregnancy dose of 17β-
oestradiol in the form of slow-release silastic implants for 18 days
suppressed Shp mRNA expression levels [52]. The reason for these
differences is not clear. However, differences in the treatment
regimen (pharmacological versus physiological oestrogen treatment,
injections versus slow-release silastic implants)might account for this
discrepancy. Moreover, differences in oestrogen effects in the above-
mentioned studies may originate from indirect effects of T3 and Gh on
oestrogen-related hepatic bile acid and lipid homeostasis. In agree-
ment with this, overlapping oestrogen effects through Er and T3 andFig. 2. Impaired hepatic Fxr function in mouse pregnancy. In mouse pregnancy, the FXR path
acid biosynthesis; ↓ Bsep, ↓Mrp3, ↓Mdr1 block BA efﬂux to the bile. Therefore, bile acids are
these alterations, represented by the dashed line in the ﬁgure.Gh on hepatic metabolism have been reported [37,60]. Remarkably, in
late pregnancy, maternal pituitary GH is suppressed as a result of
increased circulating oestrogens. As such, GH effects on hepatic
metabolism that lead to reduced fatty acid oxidation and esteriﬁcation
to ensure free fatty acid transportation to the conceptus are replaced
by placental lactogen and growth hormone [60]. Therefore, it is
possible that a gestational signal originating from the feto-placental
unit contributes to ER-dependent SHP suppression.6.2. Reduced hepatic Ppar-α function in the mouse appears to be
oestrogen-dependent
The nuclear receptor Ppar-α targets the trans-repression of the
oxysterol 7α-hydroxylase (Cyp7b1), the enzyme that catalyses the
clearance of 27-hydroxycholesterol, a competitive antagonist of
oestrogen receptor action [61]. Speciﬁcally, Er-α activation positively
regulates Cyp7b1 expression, which promotes oestrogen-induced
hepatotoxicity and intrahepatic cholestasis through elimination of 27-
hydroxycholesetrol and its conversion to oxysterol 7α-hydroxylase
that is a precursor of chenodeoxycholic acid (CDCA) in the alternative/
acidic bile acid biosynthetic pathway [35,62]. It was recently shown
that sumoylation of the ligand binding domain of Ppar-α induced
interaction of the receptor with Ga-binding protein α (Gabpα) that
was bound to the promoter of the Cyp7b1 gene. This interaction
triggered recruitment of the nuclear receptor co-repressor (Ncor),
histone deacetylases (Hdacs), and DNAmethyl transferase 3 (Dnmt3)
that in turn silenced Sp1 expression, thus leading to down-regulation
of Cyp7b1 and protection of the female liver from inﬂammation and
hepatic toxicity [53]. Protective effects of Ppar-α-induced Cyp7b1
trans-repression were further demonstrated in Ppar-α null female
mice that displayed increased Cyp7b1 mRNA expression levels,
increased serum bilirubin, and increased liver weight in response to
the oestrogen analogue 17-α-ethynylestradiol (EE2) [53].
In support of this, we showed that the down-regulation of hepatic
Ppar-α mRNA in pregnant mice (day 18 of gestation) was accompa-
nied by a~2-fold mRNA up-regulation of Cyp7b1 (unpublished data;
Fig. 3). These ﬁndings agree with the EE2-induced alterations in bile
acid and cholesterol homeostasis discussed above [35] as well as the
EE2-related inhibition of Ppar-α that has been reported in hypophy-
sectomised male rats [37].way appears blunted: ↓ Shp results in ↑ Cyp7a1 and ↑ Cyp8b1, maintaining hepatic bile
accumulated in the liver. Er signalling is a strong candidate that appears to contribute to
**
2.5
1.5
0.5
2
1
0
Fig. 3. Hepatic Ppar-α and Cyp7b1 mRNA expression in mouse pregnancy. Combined
data of 5 independent animals. Data are presented as means and standard errors. Livers
collected from pregnant (d18) and non-pregnant mice (5 mice/group) were assessed
for Ppar-α (left panel) and Cyp7b1 (right panel) mRNA (*pb0.05).
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steroid hormonal environment that maintains pregnancy is a factor
that impacts upon liver physiology. Overall activity of the orphan
nuclear receptors such as PPAR-α and FXR, as well as their
downstream targets, appears to be primarily affected by these
changes. This, in turn, leads to disruption of hepatic lipid and bile
acidmetabolism during gestation thatmay be exacerbated in high risk
individuals. Elucidating the mechanisms that mediate alterations of
hepatic nuclear receptor activity during pregnancy will expedite the
development of therapeutic strategies that target metabolism-related
complications in pregnancy and metabolic disease.7. Functional Fxr is required for normal gestational liver growth
in mouse pregnancy
Liver enlargement is one of the physiological maternal metabolic
adaptations that occur during rodent pregnancy and is essential to
support developmental nutrient demands of the fetus. Reports of
gestational liver growth go back to 1958 [63]. Other studies have also
reported pregnancy and reproductive steroid hormone-induced liver
growth [7,35], although detailed mechanisms have not yet been
identiﬁed. Bile acid nuclear receptors appear to exert key roles in the
process of liver mass reconstitution, since FXR, CAR, and PXR have
been shown to be essential for liver regeneration after partial
hepatectomy [64,65]. Moreover, it has been shown that increased
bile acids accelerate liver regeneration after hepatectomy, and
conversely, a decrease in bile acid levels inhibits liver growth [65].
Therefore, decreased levels of hepatic bile acid nuclear receptors
during pregnancy [28,29,52] may result in a net accumulation of bile
acids that, in turn, drive liver enlargement to meet increasing
demands for hepatic metabolic activity. This is in agreement with a
recent study where elevated serum bile acid levels, resulting from a
diet supplemented with 0.5% cholic acid during gestation, caused a
further increase of liver weight relative to wild-type pregnant mice.
Experiments in Pxr and Fxr null mice demonstrated that these
receptors were not involved in bile acid-induced liver enlargement
[6], indicative of another gestational signal that drives liver growth.
However, Fxr null mice did undergo gestational liver growth that was
caused by different processes compared to wild-type and Pxr null
mice. Speciﬁcally, the mechanisms that were studied as potential
drivers for hepatomegaly were the same in Pxr null mice whencompared to wild-type mice, whereas in the Fxr null mice, liver
enlargement was associated with increased hepatocyte mitosis
(hyperplasia) as well as increased hepatocyte apoptosis. These
ﬁndings demonstrated that Fxr has an essential role in the progression
of liver mass expansion during a period of increasing liver function
such as in pregnancy [6]. On the other hand, it has been proposed that
pregnancy-induced hyperplasia, as shown in Fxr null pregnantmice, is
associated with delayed restoration of liver function [66]. The switch
from hepatocyte hyperplasia to hepatocyte hypertrophy as seen in
wild-type pregnant mice appears to be a physiological response. This
results in a rapid expansion of liver mass in transient situations where
there is time-limited demand for increasing liver function such as
during pregnancy. Interestingly, it was shown that pregnancy-
induced liver hypertrophy requires activation of the Akt/mammalian
target of rapamycin c1 (mTorc1) pathway [66]. It would be of interest
to investigate whether this pathway is impaired in Fxr null pregnant
mice.
No studieshave investigated theeffects of pregnancyon liver growth
in humans. It is plausible that gestational maternal liver growth occurs
to compensate for the increasingmetabolic and nutrient developmental
demands of the feto-placental unit. Nevertheless, potential pregnancy-
induced liver growth should be less marked in humans compared to
mice, as the feto-placental unitweight-to-maternal bodyweight ratio in
the former is lower than in the latter [6]. This could be physiologically
important, as failure of human maternal liver function to proportion-
ately reﬂect the feto-placental unit weight (or metabolic load) could be
relevant to the reduced ability of thepregnantwoman to sustain hepatic
metabolic homeostaticmechanisms, thereby increasing susceptibility to
gestational liver disease.
8. Altered bile acid homeostasis in pregnancy can result in
intrahepatic cholestasis of pregnancy (ICP) in predisposed women
Intrahepatic cholestasis of pregnancy (ICP), also called obstetric
cholestasis, is the commonest liver-speciﬁc disease of pregnancy. It
has a varying incidence globally; while it affects 0.7% of pregnancies in
the UK, it affects up to 4% of pregnantwomen in Chile in recent studies
[67]. The prevalence of ICP has decreased in certain countries in recent
years, e.g., up to 10% of the Chilean population was reported to have
ICP in older studies, with higher rates in the native Araucanean
population [68]. ICP typically presents with pruritus in association
with increased maternal serum bile acids and abnormal liver function
tests. Maternal clinical and biochemical features of the condition
usually resolve rapidly after delivery, indicating that the feto-
placental unit plays a role in the aetiology of ICP. It can be complicated
by fetal distress, preterm labour, and intrauterine death [69,70]. The
largest published series of fetal complications in ICP demonstrated
that pregnancies with higher maternal serum bile acids are more
likely to have adverse fetal outcomes [70].
ICP has a complex aetiology with genetic and endocrine compo-
nents. Heterozygous mutations in the biliary transporters BSEP
(ABCB11) and MDR3 (ABCB4) have been demonstrated in a small
proportion of ICP cases [71,72] and a common single nucleotide
polymorphism (SNP) in BSEP has been shown to be a susceptibility
allele for ICP [73]. Both transporters are transcriptionally regulated by
the nuclear receptor FXR and genetic variation in FXR (NR1H4) has
also been shown in ICP cases [74]. There have also been SNPs reported
in other biliary transporters, e.g., ABCC2 [75] and ATP8B1 [72]. Thus,
the majority of genetic studies have implicated genes that are under
the transcriptional inﬂuence of FXR. It is noteworthy that normal
human and mouse pregnancy are relatively cholestatic states.
Observations to support this include the fact that asymptomatic
hypercholanaemia is a relatively common phenomenon found in
pregnant women [10,76], and raised serum and hepatic bile acids
have been reported in mouse pregnancy [52]. Therefore, it is likely
that women that harbour genetic variants of bile acid homeostasis-
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primary determinant of bile ﬂow (i.e., BSEP) are more susceptible to
the development of ICP [73,74].
The nuclear receptor PXR transcriptionally regulates genes that
inﬂuence xenobiotic metabolism. One study that sequenced the
coding sequence of PXR in 121 Caucasian ICP cases did not
demonstrate any SNPs that were associated with the disease [77].
However, a study of four tagged SNPs in 101 South American ICP cases
demonstrated a positive association between one SNP (rs2461823)
and alanine aminotransferases (ALT), aspartate aminotransferase
(AST), and bilirubin concentrations in affected women [78]. Larger
studies will establish whether genetic variation in PXR plays a role in
the aetiology of ICP.
9. The impact of pregnancy-speciﬁc endocrine signals on nuclear
receptor function
There are hepatic nuclear receptors that are not faithful to a single
ligand in the liver. Thus, it is not surprising that several molecules that
have been shown to be elevated in pregnancy (e.g., steroid hormones
and their metabolites) have the ability to modulate the activity of CAR
[79] and PXR [80].
Pregnenolone, progesterone, and their 17α hydroxylated deriva-
tives have been shown to activate human and rodent PXR, Pxr,
respectively [81]. Additionally, it has been demonstrated that
oestrone and 17β-oestradiol are able to activate rodent Car [79]. The
concentrations of these reproductive hormones shown to activate
PXR and CAR fall within levels observed during the ﬁnal trimester of
pregnancy [82,83]. Both PXR and CAR have been shown to induce
phase I and II xenobiotic metabolising enzymes [84,85]. This is
intriguing as this may link pregnancy levels of reproductive hormones
to the activation of PXR and CAR as a protective mechanism against
potentially harmful xenobiotics, offering increased protection to the
mother and fetus.
10. Expression of hepatic nuclear receptors in extrahepatic
reproductive tissues during pregnancy
Several lines of evidence have shown a role of orphan nuclear
receptors in placentation and uterine contractility. LXRs appear to
have a primary role in these processes. Recent studies have
demonstrated that deﬁciencies in LXR signalling are associated with
impaired trophoblast invasion, lipid transport towards the fetus, and
uterine contractility [86–91].
In placenta and trophoblast, Lxr transcripts are expressed
throughout gestation in mice and are detectable from early placen-
tation steps (7 days post-coitum). In humans, both LXR-α and LXR-β
transcripts are present from the 6th week of gestation. However, their
expression pattern differs. LXR-α is abundant in the yolk sac
membranes in mouse and in amniotic membranes in human, whereas
LXR-β is ubiquitously and homogenously expressed in both human
and rodents. This pattern implies distinct roles of each isoform during
choriovitellite and chorioallantoic placentation [87]. Moreover, LXR
agonists have been shown to inhibit human trophoblast invasiveness
in vitro, suggesting a role for them in implantation that might be
relevant to the pathogenesis of preeclampsia and spontaneous
abortion [88].
Placental LXR may also coordinate cholesterol transport from the
maternal to the fetal unit. This is particularly important in cases of
Smith–Lemli–Opitz syndrome where the fetus cannot synthesise
cholesterol de novo. It has been recently shown that endogenous
oxysterol-induced LXR activation triggers ABCA1- and ABCG1-
mediated cholesterol efﬂux to apolipoprotein (Apo)A-1 and high-
density lipoprotein (HDL) from human placental endothelial cells to
the fetal circulation [89]. Moreover, enhanced cholesterol transpor-ters have been shown to protect the placenta against oxidative stress
and this appeared to be LXR-regulated [86].
A role of LXR-β in the uterus has also been established.
Remarkably, in mouse uterus, Lxr-β has been shown to be a
cholesterol sensor as Lxr-β null mice accumulated cholesteryl esters
in the uterine smooth muscle cells, resulting in reduced contractile
capacity. Therefore, Lxr-β appears to be a master sensor of lipid
regulation of uterine myocytes, at least in rodents, thereby securing
the ability of the uterus to properly deliver the pups [91].
It is noteworthy that the expression and functionality of other
orphan nuclear receptors such as PXR, CAR, and FXR have been
investigated in human term placenta of healthy and diseased
pregnancy. However, data from these studies are not all consistent
so no conclusions can be made at present. Brieﬂy, trophoblast cells
extracted by whole placenta showed relatively high expression of
FXR, CAR, and PXR along with their target genes [92], whereas villous
trophoblast tissue showed very low or no expression of these
receptors (Geenes et al., unpublished data). It is important to
elucidate the extent to which there is signalling of these receptors
in placenta as this will give insights into the mechanisms that secure
fetal development and maintenance in addition to the prevention of
adverse fetal outcomes in complicated pregnancies such as in ICP.
11. Disrupted bile acid homeostasis during pregnancy could be a
result of altered circadian rhythms
Hepatic pro-cholestatic changes that take place during pregnancy
contribute to accumulation of maternal hepatic and serum bile acids
and this might be relevant to the development of ICP in genetically
predisposed women, as discussed above. Pregnancy presents a
phenotype that resembles Fxr deﬁciency, as Shp is down-regulated,
resulting in Cyp7α1 induction [52]. It is noteworthy that the bile acid
homeostasis gene proﬁle that we have observed in mouse pregnancy
also resembles mice over-expressing the nuclear receptor gene, Rev-
erb-α [27]. Rev-erb-α has been shown to be a positive regulator of bile
acid synthesis, since it directly represses Shp expression in favour
of Cyp7a1, thus maintaining bile acid synthesis. Moreover, Rev-erb-α
deﬁciency disrupts circadian rhythms of bile acid biosynthesis in
mouse [26,27]. Intriguingly, hepatic Fxr, Shp, and Rev-erb-α circadian
regulation was altered in mice that were not fed between Zeitgeber
time (ZT) 2 and ZT10 (ZT0 is at 7:00 am, when light cycle begins) for 5
days. Restricted feeding also increased the amplitude of diurnal serum
and hepatic bile acids. This phenotype was accompanied by an up-
regulation of Cyp7a1 and Ntcp mRNA expression, while Bsep mRNA
was down-regulated during this period of feeding restriction [93].
Steroid reproductive hormones appear to impact upon circadian
rhythms as oestrogens have been shown to alter hepatic circadian
expression of the peripheral clock gene Per1 [94]. Furthermore,
circadian regulation of sleep and core body temperature differs
between the follicular and luteal phases of the menstrual cycle [95]
and increased bile acids during the mid-follicular phase of the
menstrual cycle have been also reported in women [96]. These
ﬁndings indicate a direct role of the gestational hormonal environ-
ment in hepatic metabolism and hepatic circadian regulation.
Thus, changes in sleep and eating patterns as a result of the altered
hormonal milieu that typiﬁes pregnancymight well impact upon nuclear
receptor functionality that in turn may disrupt circadian regulation of
hepatic bile acid and lipid homeostasis during gestation. Identiﬁcation of
gestational circadian regulation of liver metabolism may provide further
insights for the development of strategies to prevent and treat
complicated pregnancies, especially in predisposed women.
12. Conclusions and future perspectives
It is clear that nuclear receptors are differentially regulated in
pregnancy and comprise a fundamental component of hepatic
885G. Papacleovoulou et al. / Biochimica et Biophysica Acta 1812 (2011) 879–887maternal adaptations. However, the precise mechanisms that signal
the metabolic homeostatic mechanisms that are essential to maintain
and support the feto-placental unit are yet to be identiﬁed. Oestrogens
and oestrogen metabolites appear to be strong candidates, although
the potential contribution of other endocrine components such as
progestogens and their metabolites as well as placental lactogen or
environmental factors deserves further investigation.
Attenuated functionality of nuclear receptor signalling in the liver
is amarked adaptation during pregnancy. Elucidation of themolecular
mechanisms that regulate these alterations will give insights into the
homeostatic processes that the liver undergoes under stress condi-
tions, such as pregnancy. It would be interesting to investigate
whether reduced activity of all hepatic nuclear receptors is governed
by the same signals, e.g. if oestrogens or oestrogen metabolites affect
other receptor pathways besides the PPAR-α and FXR-α pathways.
Therefore, development of agonists to target these receptors could be
of therapeutic beneﬁt. Moreover, gestational effects on nuclear
receptor pathways in energy expenditure tissues such adipose and
skeletal muscle will allow us to gain knowledge about how energy is
stored and distributed within the body of the pregnant woman to
fulﬁl nutritional developmental demands of the conceptus. Disruption
of circadian rhythms of nuclear receptors is potentially a key process
of gestational metabolic adaptations and is an exciting ﬁeld for future
study. Expression of hepatic nuclear receptors in placenta and uterus
is indicative of a major role of these receptors in placentation and
support of the fetus.
In conclusion, the ﬁeld of nuclear receptor biology in themetabolic
state of pregnancy is still at an early stage. Pregnancy is an exceptional
model to study hepatic bile acid and lipid homeostatic pathways, as
physiological gestational signals cause alterations in bile acid and lipid
homeostatic pathways. Elucidation of the molecular mechanisms that
govern these alterations as well as the time window of pregnancy
when these metabolic changes take place will allow the development
of therapeutic strategies targeted not only to the treatment of
pregnancy-induced metabolic complications but also to metabolic
disease outside pregnancy.
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